Villalvazo, P.; Marzal-Alfaro, B.; GarcÃa-Alfonso, P.; Revuelta-Herrero, J.L.; Thomas, F.; López-Tarruella, S.; GarcÃa-González, X.; Calvo, A.; Yakoubi, M.; Salvador-MartÃn, S.;
et al. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. J. Pers. Med. 2021, 11, 792.
https://doi.org/10.3390/jpm11080792
AMA Style
Villalvazo P, Marzal-Alfaro B, GarcÃa-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, GarcÃa-González X, Calvo A, Yakoubi M, Salvador-MartÃn S,
et al. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine. 2021; 11(8):792.
https://doi.org/10.3390/jpm11080792
Chicago/Turabian Style
Villalvazo, Priscila, Belén Marzal-Alfaro, Pilar GarcÃa-Alfonso, José Luis Revuelta-Herrero, Fabienne Thomas, Sara López-Tarruella, Xandra GarcÃa-González, Aitana Calvo, Malika Yakoubi, Sara Salvador-MartÃn,
and et al. 2021. "DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach" Journal of Personalized Medicine 11, no. 8: 792.
https://doi.org/10.3390/jpm11080792
APA Style
Villalvazo, P., Marzal-Alfaro, B., GarcÃa-Alfonso, P., Revuelta-Herrero, J. L., Thomas, F., López-Tarruella, S., GarcÃa-González, X., Calvo, A., Yakoubi, M., Salvador-MartÃn, S., López-López, F., Aguilar, I., Sanjurjo-Sáez, M., MartÃn, M., & López-Fernández, L. A.
(2021). DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine, 11(8), 792.
https://doi.org/10.3390/jpm11080792
